STOCKHOLM, April 29, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2025
First Quarter 2025
- Total revenue increased 3 per cent, 3 per cent at constant exchange rates, (CER)1, to SEK 6,465 M (6,256)
- Haematology revenue increased 13 per cent at CER to SEK 4,632 M (4,075), mainly driven by the launch of Altuvoct of SEK 455 M (0), strong sales of Doptelet of SEK 1,129 M (756) and sales of Aspaveli/Empaveli of SEK 333 M (240), somewhat offset by sales of Vonjo of SEK 306 M (320)
- Immunology revenue decreased 21 per cent at CER to SEK 1,526 M (1,908), explained by low Synagis sales of SEK 21 M (520) and Beyfortus royalty of SEK 189 M (318), partially offset by strong sales of Gamifant of SEK 582 M (438) and Kineret of SEK 735 M (633)
- Revenue from the strategic portfolio1* grew by 46 per cent at CER to SEK 3,255 M (2,194)
- The adjusted EBITA margin1,2 was 36 per cent (37), excluding items affecting comparability (IAC)2. EBITA1 was SEK 2,260 M (2,177), corresponding to a margin of 35 per cent (35). EBIT was SEK 1,358 M (1,313)
- Earnings per share (EPS) before dilution was SEK 2.55 (2.35) and EPS after dilution was SEK 2.52 (2.33). Adjusted EPS before dilution was SEK 2.75 (2.70) and adjusted EPS after dilution1 was SEK 2.72 (2.67)
- Cash flow from operating activities was SEK 2,295 M (2,256)
Outlook 2025 - Unchanged
- Revenue is anticipated to grow by a high single-digit percentage at CER
- The adjusted EBITA margin is anticipated to be in the mid-30s percentage of revenue
1. Alternative Performance Measures (APMs). |
2. Items affecting comparability (IAC). |
* The strategic portfolio includes Sobi's medicines Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant, Vonjo and Zynlonta, and royalty on Sanofi's sales of Altuviiio and Beyfortus.
Investors, analysts, and the media are invited to a conference call on the same day at 15:30 CET, 14:30 GMT, and 09:30 EST. The call will include a presentation of the results and a Q&A session.
The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.
To participate in the conference call, please use the following dial-in details:
Sweden: +46 8 5051 0031
United Kingdom: +44 207 107 06 13
United States: +1 631 570 56 13
For other countries, please find the details here.
Sobi
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on 29 April 2025 at 08:00 CEST.
Gerard Tobin
Head of Investor Relations
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-publishes-q1-2025-report--portfolio-continues-to-deliver,c4141715
The following files are available for download:
https://mb.cision.com/Main/14266/4141715/3415989.pdf | Q1 2025 report Portfolio continues to deliver |
View original content:https://www.prnewswire.co.uk/news-releases/sobi-publishes-q1-2025-report-portfolio-continues-to-deliver-302440755.html
